- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:42 | Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript | 2 | Benzinga.com | ||
| Fr | Vivos Therapeutics steigert Umsatz im zweiten Quartal 2026 um 35 % | 1 | Investing.com Deutsch | ||
| Fr | Vivos Therapeutics reports 35% revenue increase in Q2 2026 | 2 | Investing.com | ||
| Fr | Vivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update | 50 | GlobeNewswire (Europe) | Quarter highlighted by steadily increasing patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo.... ► Artikel lesen | |
| VIVOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Vivos Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Vivos Therapeutics, Inc: Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations | 3 | GlobeNewswire (USA) | ||
| 05.08. | Vivos Therapeutics, Inc: Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology | 308 | GlobeNewswire (Europe) | LITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing... ► Artikel lesen | |
| 03.08. | Vivos Therapeutics, Inc. - 8-K, Current Report | 20 | SEC Filings | ||
| 07.07. | Vivos Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 30.06. | Vivos Therapeutics, Inc: Vivos' Vida Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants | 14 | GlobeNewswire (USA) | ||
| 25.06. | Vivos Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.06. | Vivos Therapeutics, Inc: Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity | 239 | GlobeNewswire (Europe) | LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment... ► Artikel lesen | |
| 16.06. | Vivos Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | Vivos Therapeutics plans rights offering for shareholders | 3 | Investing.com | ||
| 11.06. | Vivos Therapeutics, Inc: Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering | 269 | GlobeNewswire (Europe) | LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment... ► Artikel lesen | |
| 10.06. | Vivos Therapeutics, Inc: Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients | 2 | GlobeNewswire (USA) | ||
| 08.06. | Vivos Therapeutics, Inc: Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026 | 2 | GlobeNewswire (USA) | ||
| 08.06. | Vivos Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | Vivos Therapeutics agrees to debt-to-equity exchange with lender | 2 | Investing.com | ||
| 05.06. | Vivos Therapeutics, Inc: Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing | 255 | GlobeNewswire (Europe) | LITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment... ► Artikel lesen |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,590 | -0,44 % | Eckert & Ziegler: Q2 review: underlying business solid, valuation attractive: Despite a slight consensus miss with Q2, ... | Eckert & Ziegler reported H1 results: adj. EBIT grew 10% yoy ex license, with the margin up 1.2pp to 22.3%, while reported adj. EBIT fell 6% yoy to € 33.3m against a base carrying € 5m of license income... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,071 | +5,97 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| SYNLAB | - | - | EQS-News: SYNLAB: Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients | EQS-News: SYNLAB
/ Key word(s): Miscellaneous
Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients
10.08.2026 / 09:00 CET/CEST
The... ► Artikel lesen | |
| CERENOME | 3,140 | -3,24 % | Cerenome, Inc.: Cerenome Reports Second Quarter 2026 Financial Results and Business Update | HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,011 | -22,22 % | XFRA 79O: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUGEN MEDICAL DEV.... ► Artikel lesen | |
| CARDINAL HEALTH | 199,30 | -1,97 % | Cardinal Health Q4 Profit Climbs, Sees Growth In FY27; Approves $5 Bln Buyback | WASHINGTON (dpa-AFX) - Healthcare services company Cardinal Health, Inc., while reporting significantly higher profit in its fourth quarter on revenue strength, on Tuesday issued fiscal 2027... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,180 | -1,80 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| INVITAE | - | - | Patentstreit: Natera sichert sich 30 % Lizenzgebühr von Invitae | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| HEARTFLOW | 42,110 | +0,07 % | Heartflow, Inc.: Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results... ► Artikel lesen | |
| FRESENIUS | 47,080 | -1,22 % | Fresenius: Fitch öffnet die Tür für ein höheres Rating | Fitch Ratings sieht bei Fresenius Fortschritte bei Bilanz und Geschäftsprofil und hebt den Kreditausblick von "stabil" auf "positiv" an. Das Rating selbst bleibt mit "BBB-" im Investment-Grade-Bereich.... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,310 | +0,69 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,040 | +0,12 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 12,310 | -0,08 % | Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen |
Das Unternehmen VIVOS THERAPEUTICS INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,343 Euro und damit -0,06 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVOS THERAPEUTICS INC finden Sie auf Wallstreet Online.